TME Pharma Presents Findings on NOX-A12 in Glioblastoma

TME Pharma N.V. has announced a poster presentation by the U.S. National Cancer Institute at the 2024 Society for Neuro-Oncology Annual Meeting. The presentation highlights research on NOX-A12, a CXCL12 inhibitor, demonstrating a synergistic effect with immune checkpoint inhibitors in brain cancer models. This combination enhances the tumor microenvironment for stronger anti-tumor immune responses. While promising for tumors outside the brain, its efficacy inside the brain remains limited.

These insights back TME Pharma's different strategies for brain and pancreas cancer. In glioblastoma, NOX-A12 is paired with anti-VEGF therapy and radiotherapy, showing double the median overall survival in clinical trials. Meanwhile, in pancreatic cancer, it's used alongside pembrolizumab, an immune checkpoint inhibitor, and chemotherapy.

Conducted at the National Cancer Institute, the research supports further exploration of NOX-A12 in combination treatments. TME Pharma continues to push boundaries in oncology therapy by targeting the tumor microenvironment.